Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Evolus announced financial results for the quarter ended September 30, 2026.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Evolus announced financial results for the quarter ended September 30, 2026
- Detailed results and management commentary are contained in Exhibit 99.1 accompanying the 8-K
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $78.0M, up 13% YoY, led by $70.1M toxin revenue and $7.9M HA gel revenue
- Adjusted EBITDA $1.2M versus $(3.1)M, marking the fourth consecutive positive quarter despite GAAP operating loss of $8.4M
- Nine-month Adjusted EBITDA $6.4M versus $(16.5)M, while net loss narrowed to $31.2M from $51.8M
- Full-year revenue guidance reaffirmed at $330M to $337M, with non-GAAP operating expense guidance reduced to $210M to $213M
- Cash $41.7M plus approximately $120M non-dilutive capacity, but inventory rose to $82.8M and long-term debt reached $156.9M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.